Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide Journal Article

   


Authors: Huang, P. A.; Beedie, S. L.; Chau, C. H.; Venzon, D. J.; Gere, S.; Kazandjian, D.; Korde, N.; Mailankody, S.; Landgren, O.; Figg, W. D.
Article Title: Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
Abstract: Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy. In this study, we assessed the correlation of five single nucleotide variants (SNVs) in the CRBN gene with clinical response and outcomes in patients with NDMM administered KRd therapy with lenalidomide maintenance, achieving favorable trial endpoints in a prospective Phase II study (NCT01402284). Of the observed SNVs, no associations with KRd therapy response were found in this patient cohort, although strong trends in hypoalbuminemia grade and hyperbilirubinemia grade emerged across the CRBN rs1672753 genotype (P = 0.0008) and the rs1714327 genotype (P = 0.0010), respectively. Our results do not provide conclusive support for the predictive utility of CRBN gene polymorphisms as potential biomarkers of clinical response to lenalidomide-based therapy in our patient population. However, these findings remain to be validated in prospective studies using larger patient populations. © 2019, The Author(s).
Journal Title: Scientific Reports
Volume: 9
ISSN: 2045-2322
Publisher: Nature Publishing Group  
Date Published: 2019-01-01
Start Page: 14884
Language: English
DOI: 10.1038/s41598-019-51446-9
PUBMED: 31619706
PROVIDER: scopus
PMCID: PMC6795854
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073462650&doi=10.1038%2fs41598-019-51446-9&partnerID=40&md5=a71439b8e3d02f1457bd0800a4e3078d
Notes: Article -- Export Date: 1 November 2019 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Carl Ola Landgren
    336 Landgren
  2. Neha Sanat Korde
    226 Korde
  3. Sham Mailankody
    282 Mailankody
Related MSK Work